Dr Reddy’s, Hetero ink royalty-free voluntary licencing pacts with Gilead Sciences for HIV drug Lenacapavir – Times of India

[ad_1] Dr Reddy’s Laboratories HYDERABAD: Dr Reddy’s Laboratories and Hetero are among half a dozen generic drug makers to have entered into non-exclusive, royalty-free voluntary licencing agreements with Gilead Sciences Ireland UC to manufacture and distribute the latter’s human immunodeficiency virus (HIV) drug Lenacapavir in India and 120 low- and middle-income countries (LMICs).Apart from Dr…

Read More

Dr Reddy’s initiates voluntary recall of Sapropterin Dihydrochloride in US over potency concerns – Times of India

[ad_1] HYDERABAD: Dr Reddy’s Laboratories Ltd on Tuesday informed the bourses that it has initiated a voluntary recall of six lots of Sapropterin Dihydrochloride powder for oral solution 100 mg in the US market.The company said that though it has not received any reports of adverse events related to the recalled product till date, it…

Read More

Dr Reddy’s rolls out migraine management device Nerivio in Europe – Times of India

[ad_1] HYDERABAD: Less than six months after it rolled out wearable migraine management device Nerivio in the Indian market, Dr Reddy’s Laboratories has now rolled out the drug-free, non-invasive device in the European market.The company has launched Nerivio in Germany to start with through its step-down subsidiary betapharm, marking its foray into digital therapeutics in…

Read More

Dr Reddy’s ties up with US firm for resuscitative therapy – Times of India

[ad_1] NEW DELHI: Dr Reddy’s has entered into a licence agreement with Pharmazz, a US based biopharmaceutical company, to commercialise a first-in-class innovative drug Centhaquine in India.Developed by Pharmazz, Centhaquine is a resuscitative agent, presently indicated for the treatment of hypovolemic shock, by the Drugs Controller General of India (DCGI), says a company statement.As per…

Read More